Contact OAR

Advocacy

Federal Update: CMS Medicare Part B Proposal Draws Criticism

posted: April 1, 2016

More than 300 groups, including the Ohio Association of Rheumatology, are urging House and Senate leadership to press CMS to permanently withdraw the Innovation Center experiment to overhaul payments for Part B drugs. Work is also ongoing with federal lawmakers, to garner additional pressure on the administration regarding the proposal.

FDA Guidance and Biologics 2020

Some medical products regulated by FDA as drugs will be considered biologic medicines come March 23, 2020 per the biologics law created under the Affordable Care Act. With that change FDA says that any unexpired period of exclusivity for a transitional product -those approved as drugs that will convert to biologics in 2020.